An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability

scPharmaceuticals, Inc.1 个研究点分布在 1 个国家目标入组 39 人开始时间: 2019年12月2日最近更新: 2020年7月10日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: scPharmaceuticals, Inc.
入组人数: 39
试验地点: 1
主要终点: Infusion Site Pain (11 Point Pain Scale)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous infusions of Furoscix.

详细描述

Furoscix 80 mg will be administered as a subcutaneous infusion following a step-wise decrease in infusion times starting with a 5 hour infusion time. Subsequent cohorts will enroll following a safety assessment of the prior cohort. While maintaining the 80 mg dose, infusion time will ultimately be reduced to 30 minutes.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Other
盲法: None

入排标准

年龄范围: 45 Years 至 80 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Subjects are eligible for inclusion only if all of the following criteria are met:
•An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities.
•Male and female Subjects 45-80 years of age.
•Have the ability to understand the requirements of the study and is willing to comply with all study procedures.
•In the opinion of the investigator, able to participate in the study.

排除标准

•A Subject is not eligible for inclusion if any of the following criteria apply:
•Receipt of loop diuretics (furosemide, bumetanide or torsemide) or thiazide diuretics (hydrochlorothiazide or metolazone) within 24 hours of study drug.
•Receipt of potassium-sparing diuretics (spironolactone, amiloride) or oral calcium, potassium or magnesium supplements (including multi-vitamins) within 24 hours of study drug.
•History of allergy to furosemide, sulfonamides or other loop diuretics.
•Any skin conditions currently requiring medical therapy.
•History of diabetes.
•Presence or need for urinary catheterization, urinary tract abnormality or disorder interfering with urination.
•Serum sodium <130 mEq/L at screening.
•Serum potassium < 3.5 or > 5.5 mEq/L at screening.
•Serum magnesium < 1.5 or > 2.5 mEq/L at screening.
•Serum chloride < 96 or > 106 mEq/L at screening.
•Serum calcium < 8.5 or > 10.5 mg/dL at screening.
•Estimated Glomerular Filtration Rate (GFR) < 30 mL/min/1.73 m2 by simplified Modification of Diet in Renal Disease (sMDRD) equation at screening.
•Systolic BP (SBP) < 90 mm Hg at screening or baseline.
•Heart rate > 110 beats per minute (BPM) at screening or baseline.
•History of tinnitus or hearing impairment, including deafness.
•Temperature > 38°C (oral or equivalent) at screening or baseline.
•Blood alcohol concentration > 2 mg/dL (0.02%) at screening or baseline.
•Female Subject who is pregnant or lactating.
•History of major abdominal surgery affecting the needle placement site.
•History of benign prostatic hyperplasia (BPH), prostatitis or prostate cancer.
•Urinary retention due to bladder emptying disorders and/or urethral narrowing.
•History of liver disease, cirrhosis, or ascites.
•Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema, etc.
•Allergies and/or sensitivities to adhesive bandages or medical tape.
•Any surgical or medical condition which in the opinion of the Investigator may interfere with participation in the study or which may affect the outcome of the study.